Company Overview - Vor Bio is a clinical-stage cell and genome engineering company focused on transforming the standard of care for patients with blood cancers by engineering hematopoietic stem cells for targeted therapies post-transplant [3]. Event Participation - Vor Bio will participate in a fireside chat and host virtual 1x1 investor meetings at Oppenheimer's 35th Annual Healthcare Life Sciences Conference [1]. - The fireside chat is scheduled for Wednesday, February 12 at 12:00pm ET and will be available via live webcast and archived replay on the company's investor section [2].

Technical Analysis - Vor Biopharma Inc. (VOR) has reached a key level of support, with its 50-day simple moving average crossing above its 200-day simple moving average, indicating a "golden cross" [1] - A golden cross is a technical chart pattern that suggests a bullish breakout may be imminent, typically involving the 50-day and 200-day moving averages [1][2] Market Performance - VOR has experienced a rally of 15.4% over the past four weeks, positioning the company as a 2 (Buy) on the Zacks Rank, suggesting potential for further breakout [3] - The positive earnings outlook for the current quarter supports the bullish case, with no earnings estimates decreasing in the past two months and one revision higher, alongside an increase in the Zacks Consensus Estimate [3][4] Investor Sentiment - Given the positive technical indicators and the upward movement in earnings estimates, VOR may be an attractive option for investors seeking gains in the near future [4]

Company Overview - Vor Bio is a clinical-stage cell and genome engineering company focused on changing the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant [5] Key Appointment - Mr. Erez Kalir has been appointed to Vor Bio's Board of Directors, representing a new seat created in connection with a recent private investment in public equity financing (PIPE) led by Reid Hoffman [1] - Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman’s investment fund [1] Mr. Kalir's Background - Mr. Kalir has extensive experience as an investor, entrepreneur, and thought leader in life sciences and technology [2] - He is currently the Managing Member of Martial Eagle Fund and a Venture Partner at FJ Labs, known for early-stage venture investments [2] - Mr. Kalir has authored the influential Biotech Frontiers newsletter, providing analysis on cutting-edge biotech companies [2] - His educational background includes an MSc in cell biology from Magdalen College, Oxford, a JD from Yale Law School, and an A.B. with highest honors from Stanford University [4] Strategic Vision - Dr. Robert Ang, President and CEO of Vor Bio, expressed excitement about Mr. Kalir's appointment, highlighting his extensive biotech experience and track record in fostering innovation [3] - Matthew R. Patterson, Chairman of Vor Bio, welcomed Mr. Kalir and emphasized the importance of his contributions as the company advances its clinical programs and strategic vision [3] Future Goals - Mr. Kalir expressed his commitment to working with Vor Bio's management team to advance their trem-cel platform and VCAR33 through the regulatory approval process, aiming for life-changing impacts for patients [4]

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securities purchas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Core Insights - Vor Bio has appointed Han Choi, M.D., LL.M., as the new Chief Financial Officer, effective immediately [1][3] - Dr. Choi brings over 25 years of experience in investment management, business development, and corporate strategy within the pharmaceutical and biotechnology sectors [2][3] - The company aims to transform treatment outcomes for patients with acute myeloid leukemia (AML) and other blood cancers through innovative cell and genome engineering [4] Company Overview - Vor Bio is a clinical-stage company focused on cell and genome engineering, specifically targeting blood cancers by engineering hematopoietic stem cells for post-transplant therapies [4] - The company is advancing its clinical pipeline and expanding its leadership in the field [2] Leadership Background - Dr. Choi previously served as a Principal at Oracle Investment Management, specializing in healthcare investments, where he managed investments in the pharmaceutical and biotechnology sectors [3] - He has held significant roles in licensing and business development at Pharmacia Corporation and Bristol-Myers Squibb Company [3] Compensation Details - As part of his appointment, Dr. Choi was granted stock options to purchase 400,000 shares of Vor Bio's common stock [5] - The stock options have a ten-year term with an exercise price equal to the closing price on September 30, 2024, and will vest over four years [6]

Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg. Pfizer Inc's PFE Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients two years and older. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broad ...

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with rela ...

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference 1x1 Investor Meetings: Friday, September 6, 2024 Location: New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024, at 7:55am ET Location: New York, NY Chardan's 8th Annual Genetic Medicines Confe ...

The stock options have a ten-year term and an exercise price of $1.41 per share, which is equal to the closing price of Vor Bio's common stock on June 3, 2024. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remai ...